Ocular FIP treatment enters a more evidence-based era: full analysis

CURRENT FULL VERSION: Ocular FIP is moving from a once-hopeless diagnosis toward a treatable, if still complex, clinical problem. That’s the premise behind VetGirl’s recent podcast on antiviral therapy for feline infectious peritonitis with ocular involvement, which highlights a growing body of evidence around remdesivir and GS-441524 in cats whose disease affects the eye. The headline change for clinicians is not that ocular FIP has become simple, but that treatment decisions are increasingly grounded in published dosing experience, survival data, and real-world access to compounded antiviral therapy. The podcast also serves as a reminder that ocular disease may be the presenting face of FIP: some cats come in primarily for uveitis or vision change, and eye findings can be the first clue to a broader systemic process. (music.amazon.com)

The backdrop here is how quickly the FIP landscape has changed. Untreated FIP remains almost uniformly fatal, but antiviral treatment has transformed outcomes over the past several years. In one large retrospective study of 108 cats treated with IV remdesivir, oral GS-441524, or both, published in JVIM in 2025, most cats survived the initial treatment period, and the authors noted that prior studies had reported survival rates in the 81% to 86% range after 84-day treatment courses. A separate clinical reference for practitioners summarizes overall survival across reports at roughly 77% to 100%, while emphasizing that differences in formulation quality, case definition, and follow-up make direct comparisons difficult. (academic.oup.com)

For ocular disease specifically, the available literature supports a more aggressive approach than standard-dose treatment for uncomplicated effusive cases. A JVIM case series of 32 cats treated with remdesivir and GS-441524 reported that cats with neurologic or ocular FIP were started at 15 to 20 mg/kg every 24 hours, reflecting concern about drug penetration into the eye and central nervous system. Clinician-facing guidance echoes that point, noting that cats with neurologic and ocular forms appear to require larger doses because the medication must reach tissues behind the blood-eye and blood-brain barriers as vasculitis evolves and those barriers heal. The VetGirl discussion places that dosing issue in a practical ophthalmic context: ocular FIP can involve anterior chamber changes such as keratic precipitates, iris color change, dyscoria or anisocoria, hyphema, hypopyon, and fibrinous exudate, as well as posterior segment lesions including tapetal or non-tapetal inflammatory lesions, retinal hemorrhage or vascular tortuosity, retinal detachment, and perivascular cuffing. Those findings may be unilateral or bilateral, and they can precede a more obvious systemic diagnosis. (academic.oup.com)

The podcast also recaps an important clinical pattern: while FIP is still often described as effusive versus non-effusive, those forms overlap pathologically, and ocular and neurologic involvement are seen much more often in dry FIP than in wet disease. VetGirl cites ocular involvement in roughly 36% of non-effusive cases versus about 5% of effusive cases, while also noting that an ocular-signs-dominant presentation can occur. For general practitioners and ER teams, that matters because a cat presenting for uveitis, dyscoria, or retinal changes may still warrant a systemic FIP workup even without classic wet-FIP effusion. (music.amazon.com)

The regulatory context matters, too. In the U.S., compounded GS-441524 became available for veterinary prescribing in June 2024, and the FDA said it does not intend to enforce new animal drug approval requirements for products compounded from GS-441524 when prescribed by a veterinarian for a specific cat patient under the conditions in Guidance for Industry #256. That doesn’t make the drug FDA-approved, but it has materially changed access and given veterinarians a more defensible option than unlicensed internet-sourced formulations, whose content and quality may vary. (cliniciansbrief.com)

There are still important caveats. The evidence base for shortening treatment is promising, but not yet definitive for ocular disease. Commentary from infectious disease specialist Dr. Scott Weese on the 2024 German 42-day trial called the findings “game changing” for some cats with effusive FIP, but he specifically warned against broadly extrapolating those results to neurologic or ocular cases because those subgroups were minimally represented. In the same vein, the 2025 JVIM mortality study found that some cats needed dose increases during the initial 84-day course, and all seven cats whose doses were increased for incomplete clinical or laboratory resolution survived without relapse. (wormsandgermsblog.com)

Expert and industry commentary has increasingly focused on using legitimate, pharmaceutical-grade compounded products and on tailoring protocols to disease severity. Clinician’s Brief advises that treatment usually consists of daily oral or injectable therapy, or both, for 12 weeks, with roughly 10% of cats in one large retrospective study relapsing during or after treatment, most within 60 days after stopping. Some of those cats responded to repeat treatment at the same or higher dose. That’s especially relevant for ocular FIP, where incomplete penetration or delayed recognition of progression could leave clinicians needing to intensify therapy rather than abandon it. (cliniciansbrief.com)

Why it matters: For veterinary teams, ocular FIP now sits in a very different clinical and ethical space than it did even two years ago. The key job is no longer only diagnosis and prognosis, but also protocol selection, sourcing, monitoring, and expectation-setting with pet parents. Ocular findings should prompt consideration of higher-dose antiviral plans, careful ophthalmic follow-up, and frank discussion that response can be strong, but treatment may be longer, more expensive, or more adjustable than in straightforward wet FIP. Just as importantly, those eye findings may be the entry point to diagnosis, not merely a late complication, so recognizing the characteristic anterior and posterior segment changes can speed treatment decisions. The 2025 JVIM study also suggests prognosis is shaped by overall disease severity, with increased plasma LDH activity emerging as a potential predictor of short-term mortality, underscoring the need to monitor the whole patient, not just the eye. (cliniciansbrief.com)

What to watch: The next big developments are likely to be more protocol-specific data for ocular and neurologic FIP, including randomized comparisons of oral GS-441524 versus remdesivir, better criteria for when shorter courses are safe, and clearer relapse-management strategies as legal U.S. access to compounded therapy matures. Just as important will be more granular outcome data tied to specific ocular presentations, since clinicians still need better evidence on whether cats with vision-threatening anterior uveitis, retinal disease, or mixed ocular-neurologic involvement can safely follow the same timelines as less complicated FIP cases. (academic.oup.com)